Clinical Trial Update: Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating glembatumumab vedotin in patients with metastatic or locally recurrent uveal melanoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• Glembatumumab Vedotin (glembatumumab vedotin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7 | Phase 2 | Status: COMPLETED | Results posted: 2020-08-21